Insilico Medicine
Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.
Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelioma and solid tumours). Profitable in H1 2026 on licensing revenue.
Pages like this
not linked directly; found by shared links- Key paperAlphaFold 2: predicting protein structures to near-experimental accuracy
Shares De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product.
- InstitutionCentro Nacional de Investigaciones Oncológicas (CNIO)
Shares KRAS & RAS inhibitors, AI-driven drug & target discovery, KRAS, Pancreatic ductal adenocarcinoma.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- PersonAndrew J. Aguirre
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyIsomorphic Labs
Shares De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product.
- IdeaSelf-driving laboratories that run the cancer biology hypothesis loop autonomously
Shares AI-driven drug & target discovery, The valley of death between lab and product, KRAS.
- CompanyGenerate:Biomedicines
Shares De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product.